Pamela Klein
Follow
Get notifications in MyBN when activity occurs.
Pamela Klein
Non-Executive Director / Patrys
Dr Pamela Klein has over 20 years of experience in the oncology and biopharmaceutical industry.
Dr Klein is a company director of Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in the areas of cancer and severe autoimmune disease. She is also on the board of Spring Bank Pharmaceuticals (NASDAQ), a clinical stage biopharmaceutical company developing therapeutics for both HBV and oncology.
Dr Klein is the principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development. Prior to that, she was the chief medical officer of Intellikine, vice president of development at Genentech where she led the development of portfolio of drugs including the Human Epidermal Receptor: HER (Herceptin, Tarceva, Perjeta), Apoptosis and Hematology compounds including Rituxan. Several of these, such as Herceptin and Rituxan, became the foundation for the new standard of care for HER2+ breast cancer and numerous hematologic malignancies/autoimmune diseases respectively.
Dr Klein is a company director of Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in the areas of cancer and severe autoimmune disease. She is also on the board of Spring Bank Pharmaceuticals (NASDAQ), a clinical stage biopharmaceutical company developing therapeutics for both HBV and oncology.
Dr Klein is the principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development. Prior to that, she was the chief medical officer of Intellikine, vice president of development at Genentech where she led the development of portfolio of drugs including the Human Epidermal Receptor: HER (Herceptin, Tarceva, Perjeta), Apoptosis and Hematology compounds including Rituxan. Several of these, such as Herceptin and Rituxan, became the foundation for the new standard of care for HER2+ breast cancer and numerous hematologic malignancies/autoimmune diseases respectively.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1506th | Patrys | -50% | -26% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Patrys | $1.3m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Non-Executive Director, Patrys | 03 Nov 2020 |
